Tobramycin sulfate


Home > Drug Prescribing Database > T > Tobramycin sulfate Dosage, Interactions, Side Effects, How to Use

Related Categories: Tobrex (Ophthalmic)

Tobramycin sulfate Questions

Ask a Question...

INHALED TOBRAMYCIN by LYNN HOFF, RRT from Steubenville, OH 02/25/2007

Tobramycin question by Robyn Lister from Australia 05/17/2006

I would like to know about the inhalent of Tobramycin, and what effects it has on the by Jean from El Cajon, CA 01/15/2006

Tobramycin sulfate
Tobramycin sulfate (Nebcin)
Tobramycin sulfate
(toe-brah- MY-sin)
Pregnancy Category: D (B for ophthalmic use) Inhalation: TOBI Parenteral: Nebcin Nebcin Pediatric Ophthalmic: AKTob Ophthalmic Solution Tobrex Ophthalmic Ointment Tobrex Ophthalmic Solution (Rx)

Classification: Antibiotic, aminoglycoside

See Also: See also Aminoglycosides .

Action/Kinetics: Similar to gentamicin and can be used concurrently with carbenicillin. Therapeutic serum levels: IM, 4-8 mcg/mL. t 1/2: 2-2.5 hr. Toxic serum levels: > 12 mcg/mL (peak) and > 2 mcg/mL (trough).

Uses: Systemic: (1) Complicated and recurrent UTIs due to Pseudomonas aeruginosa, Proteus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Staphylococcus aureus, Citrobacter and Providencia. (2) Lower respiratory tract infections due to P. aeruginosa, Klebsiella, Enterobacter, E. coli, Serratia and S. aureus (penicillinase- and non-penicillinase producing). (3) Intra-abdominal infections (including peritonitis) due to E. coli, Klebsiella and Enterobacter. (4) Septicemia in neonates, children, and adults due to P. aeruginosa, E. coli and Klebsiella. (5) Skin, bone, and skin structure infections due to P. aeruginosa, Proteus, E. coli, Klebsiella, Enterobacter and S. aureus. (6) Serious CNS infections, including meningitis. Can be used with penicillins or cephalosporins in serious infections when results of susceptibility testing are not yet known.
Ophthalmic: Treat superficial ocular infections due to Staphylococcus, S. aureus, Streptococcus, S. pneumoniae beta-hemolytic streptococci, Corynebacterium, E. coli, Haemophilus aegyptius, H. ducreyi, H. influenzae, H. parainfluenzae, Klebsiella pneumoniae, Neisseria, N. gonorrhoeae, Proteus, Acinetobacter calcoaceticus, Enterobacter, Enterobacter aerogenes, Serratia marcescens, Moraxella, Pseudomonas aeruginosa and Vibrio.


Inhalation: Management of lung infections ( P. aeruginosa) in cystic fibrosis clients .

Contraindications: Ophthalmically to treat dendritic keratitis, vaccinia, varicella, fungal or mycobacterial eye infections, after removal of a corneal foreign body. Lactation.

Special Concerns: Use with caution in premature infants and neonates. Ophthalmic ointment may retard corneal epithelial healing.

Additional Side Effects: Ophthalmic use: Transient irritation, burning, stinging, itching, inflammation, angioneurotic edema, urticaria, vesicular and maculopapular dermatitis.

Overdose Management: Symptoms (Ophthalmic Use): Edema, lid itching, punctate keratitis, erythema, lacrimation.

Additional Drug Interactions: Carbenicillin or ticarcillin: Tobramycin effect when used for Pseudomonas infections.

How Supplied: Inhalation Solution: 60 mg/mL; Injection: 10 mg/mL, 40 mg/mL; Powder for injection: 60 mg, 80 mg, 1.2 g; Ophthalmic Ointment: 0.3%; Ophthalmic Solution: 0.3%

Dosage
?IM, IV Non-life-threatening serious infections.
Adults: 3 mg/kg/day in three equally divided doses q 8 hr.
Life-threatening infections.
Up to 5 mg/kg/day in three or four equal doses. Pediatric: Either 2-2.5 mg/kg q 8 hr or 1.5-1.9 mg/kg q 6 hr; neonates 1 week of age or less: up to 4 mg/kg/day in two equal doses q 12 hr.
Impaired renal function.
Initially: 1 mg/kg; then, maintenance dose calculated according to information supplied by manufacturer.
?Ophthalmic Ointment (0.3%) Acute infections.
0.5-in. ribbon q 3-4 hr until improvement is noted.
Mild to moderate infections.
0.5-in. ribbon b.i.d.-t.i.d.
?Ophthalmic Solution (0.3%) Acute infections.
Initial: 1-2 gtt q 15-30 min until improvement noted; then, reduce dosage gradually.
Moderate infections.
1-2 gtt 2-6 times/day.
?Inhalation Solution Pseudomonas aeruginosa in cystic fibrosis.
Dose using a nebulizer b.i.d. for 10-15 min in cycles of 28 days on and then 28 days off. See package insert for detailed instructions for administration.